Lorus Therapeutics (Thread 1) - 500 Beiträge pro Seite

[OesiStockpicker]

Lorus Therapeutics-Aktien legen um 20% zu, weil Krebsmedikamente Wirkung zeigen
von Redaktion WO, 28.02.00 18:00:06 539710
Das Biotech-Unternehmen Lorus Therapeutics Inc. (LORFF) stieg im heutigen Handelsverlauf bis
auf ein Tageshoch von 2 7/8$. Aktuell notieren die Titel an der NASDAQ zu einem Kurs von 2
5/8$. Ein Plus von 27/64$ oder 19,32 Prozent.

In klinischen Tests wurde nachgewiesen, so das Unternehmen, dass zwei der
Krebs-Medikamente von Lorus signifikante Tumor-Rückbildungen bei Mäusen verursacht hatten.
Denen waren im Vorfeld Zellen verabreicht worden, die menschlichen Prostata-Krebs enthielten.



von polyte, 04.03.00 20:40:21 569534
Hat irgendjemand hier eine Meinung oder irgendwelche weiteren infos ??
Die Kanadier sind ganz heiss auf diesen Wert.

Die MK ist gerade bei 500 Mio.CAN$. Und das beste: weniger als 30% der Aktien im free float
(von 120 Mio.).

Der Wert war lange absolut im Keller und ist voruebergehend aus dem NASDAQ geflogen, soll
aber jetzt ganz schnell wieder regulär gelistet werden (bei Wert über 4$).

Der Wert wird auch in Kanada (eigentlich kanadischer Wert) gehandelt (TSE: LOR).
Weitere Infos (ausführlicher report): http://www.stockhouse.ca/shfn/mar00/030300ca_lorus.asp
Tut mir leid, aber ich weiss nicht, wie man den Link aktiviert.

Ich glaube, das ist eine echt Riesenchance, bei einem Biotech-Wert nich recht frueh dabei zu
sein.

Danke fuer Meinungen!
polyte



von OesiStockpicker, 31.03.00 18:46:01 732378
Hier die letzte News:
Findings On Lorus Therapeutics` - TSE:LOR; OTCBB:LORFF - Lead
Anti-Cancer Drug Presented At Annual Meeting of American Association
for Cancer Research

GTI-2040 Shows Excellent Anti-Tumor Activity and Safety Profile in Animal Models; Support for
Ongoing Clinical Trial

TORONTO--(BUSINESS WIRE)--March 30, 2000-- Lorus Therapeutics Inc. ("Lorus") (TSE: LOR.)
(OTCBB: LORFF)
reported today that its lead anti-cancer drug, GTI-2040, will be featured at the 91st Annual
Meeting of the American Association
for Cancer Research (AACR) in San Francisco, April 1-5, 2000. Dr. Jim Wright, president and
chief scientific officer of Lorus,
will deliver two presentations profiling GTI-2040`s anti-tumor properties and the results of
toxicology studies performed with
GTI-2040.

In the first presentation, Dr. Wright will describe the impact of GTI-2040 on mouse models. Lorus
found that when levels of
ribonucleotide reductase, a gene which plays an important role in cancer progression, were
reduced during treatment with
GTI-2040, marked inhibition of human tumor growth was observed. The mouse models included a
wide variety of human tumors,
including those derived from the most common human cancers. The responses to treatment with
GTI-2040 included significant
tumor growth reduction, disease stabilization (i.e., very little or no tumor growth), and tumor
regressions.

The second presentation will detail how GTI-2040 was well tolerated in toxicology studies using
rhesus monkeys, even when they
were treated with higher dosage levels than Lorus expects will be required to show anti-tumor
activity in human clinical trials.

"The results of these two investigations, which demonstrate both the outstanding anti-tumor
potential of GTI-2040 and that the
drug is well tolerated in primates even at very high doses, are extremely encouraging," said
Philippe G. Lacaille, chair and chief
executive officer of Lorus Therapeutics Inc. "These studies support the Phase I/II clinical trial of
GTI-2040 that is presently in
progress under the direction of Dr. Richard Schilsky at the University of Chicago Cancer
Research Center."

The clinical trial of GTI-2040 is underway, patient enrollment is on schedule, and to date, dosing
appears to be well tolerated
without any apparent safety issues.

Founded in 1907, the American Association for Cancer Research is a professional society of
more than 15,000 laboratory and
clinical scientists engaged in cancer research in the United States, Canada, and more than 60
other countries. The AACR`s
principal activities include: fostering advances in cancer and biomedical research through
programs that promote scientific
communication, science education and training, and public education; organizing scientific
meetings for the presentation of new and
significant discoveries in the cancer field; and publishing four [leading, preeminent] peer-reviewed
scientific journals (Cancer
Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology,
Biomarkers & Prevention).

Lorus is a biopharmaceutical company focused on the research and development of cancer
therapies. Lorus` goal is to capitalize
on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates
that can be used, either alone, or
in combination, to successfully manage cancer. Through an active acquisition and in-licensing
program, Lorus is building a portfolio
of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in
cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on
the Toronto Stock Exchange
under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which
reflect the Company`s current
expectation regarding future events. These forward-looking statements involve risks and
uncertainties, which may cause actual
results to differ materially from those statements. Those risks and uncertainties include, but are
not limited to, changing market
conditions, the successful and timely completion of clinical studies, the establishment of
corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties related to the regulatory
approval process, and other
risks detailed from time-to-time in the Company`s ongoing quarterly filings, annual reports and
20-F filings.

Lorus Therapeutics Inc.`s press releases are available through the Company`s Internet site:
www.lorusthera.com.

Contact:

Investor Relations:
Investor Relations Exchange
Mimi Choi, 416/599-6152
416/599-8429 (FAX)
Email: [e-mail] or [e-mail]
or
Media Relations:
Mansfield Communications Inc.
Julija Hunter or Pereina Choudhury, 416/599-0024
416/599-7484 (FAX)
Email: [e-mail] or [e-mail]


Irgendjemand in Lorus investiert????????????????
p.s: ich bin`s!



Antwort schr

[OesiStockpicker]

Hier die letzten News; scheint so, als wir ich der einzige hier, der in diesen Wert investiert ist:

Lorus Therapeutics Announces Inclusion In TSE 300

TORONTO--(BUSINESS WIRE)--April 25, 2000--(TSE: LOR) (OTCBB: LORFF) Philippe G. Lacaille, chairman and chief
executive officer of Lorus Therapeutics Inc. ("Lorus"), is pleased to announce that Standard & Poors added Lorus to the TSE 300
Composite Index(R) after the market close on April 19, 2000.

The TSE 300 Composite Index(R) (TSE 300), introduced in 1977, was created by the Toronto Stock Exchange and is maintained
by Standard & Poors. It is composed of the 300 largest Canadian public companies on the TSE and is regarded as a barometer of
activity in the Canadian markets. Standard & Poors reviews and follows strict criteria regarding inclusion and makes adjustments
accordingly.

"We are very proud to be part of this select group of Canadian public companies," said Philippe G. Lacaille, chairman and chief
executive officer of Lorus Therapeutics Inc. "The TSE 300 is the standard bearer of the Canadian stock market. We would like to
take this opportunity to thank our shareholders for their support of our research and development of innovative cancer therapies."

The TSE 300 Composite Index(R) was created by The Toronto Stock Exchange and is maintained by Standard & Poors. Standard
& Poors in consultation with The Toronto Stock Exchange reserves the right to include or exclude any stock within the TSE 300
Composite Index as it may in its sole and absolute discretion determine. The Criteria for Inclusion are continually reviewed with
the advice of, and in consultation with, the Index Committee and may be subject to change at any time.

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus` goal is to capitalize
on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or
in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio
of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange
under the symbol LOR, and on the NASDAQ OTC BB exchange under the symbol LORFF.

Except for historical information, this press release contains forward-looking statements, which reflect the Company`s current
expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual
results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other
risks detailed from time-to-time in the Company`s ongoing quarterly filings, annual reports and 20-F filings.

Lorus Therapeutics Inc.`s press releases are available through the Company`s Internet site: www.lorusthera.com.

Contact:

Investor Relations:
Investor Relations Exchange, 416/599-6152
416/599-8429 (FAX)
Email: [e-mail]
or
Media Relations:
Mansfield Communications Inc., 416/599-0024
416/599-7484 (FAX)
Email: [e-mail] or [e-mail]

[OesiStockpicker]

Gerade via e-mail erhalten:

LOR.) Lorus Raises $46 Million In Bought Deal Financing

TORONTO, May 2, 2000 (BUSINESS WIRE) -- Lorus Therapeutics Inc. (NASDAQ:LORFF)
(TSE:LOR.)("Lorus") today announced that it has completed a bought deal
financing with a syndicate of underwriters to issue and sell 15,333,334 Common
Shares of Lorus Therapeutics Inc. at a price of $3.00 per Common Share for gross
proceeds of $46 million. This includes an option, which has been exercised in
full by the underwriters, to purchase up to 2,000,000 additional Common Shares
at $3.00.

The syndicate of underwriters was led by HSBC Securities (Canada) Inc. and
includes Yorkton Securities Inc., TD Securities Inc. and Dominick & Dominick
Securities Inc. As previously announced, Lorus filed a final short form
prospectus with the securities commissions and similar regulatory authorities in
all Canadian provinces to qualify the issuance of the Common Shares.

Net proceeds of the offering will be used for the development of the Company`s
antisense and small molecule anti-cancer drugs, to build increased value in
Virulizin(R) through a pivotal Phase III trial, to support the research and
development costs of acquired technologies, and for general corporate purposes.

"We thank our shareholders for their strong support and confidence in our
strategy of building a leading cancer therapy company, as evidenced by the
success of this financing," said Philippe G. Lacaille, chairman and chief
executive officer of Lorus Therapeutics Inc. "With this solid financial
platform, Lorus can reduce the `time to market` for each of our key oncology
drugs."

Lorus is a biopharmaceutical company focused on the research and development of
cancer therapies. Lorus` goal is to capitalize on its research, pre-clinical,
clinical and regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination, to successfully manage cancer. Through an
active acquisition and in-licensing program, Lorus is building a portfolio of
promising anti-cancer drugs. Late-stage clinical developments and marketing will
be done in cooperation with strategic pharmaceutical partners.

Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the
Toronto Stock Exchange under the symbol LOR, and on the NASDAQ OTC BB exchange
under the symbol LORFF.

Except for historical information, this press release contains forward-looking
statements, which reflect the Company`s current expectation regarding future
events. These forward-looking statements involve risks and uncertainties, which
may cause actual results to differ materially from those statements. Those risks
and uncertainties include, but are not limited to, changing market conditions,
the successful and timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and pricing, new product
development, uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company`s ongoing quarterly filings,
annual reports and 20-F filings.

Lorus Therapeutics Inc.`s press releases are available through the Company`s
Internet site: www.lorusthera.com.


Distributed via COMTEX.

Copyright (C) 2000 Business Wire. All rights reserved.